open access

Vol 14, No 2 (2017)
Review paper
Get Citation

Pharmacological properties of serotonin and norepinephrine reuptake inhibitors — case of duloxetine

Przemysław Bieńkowski
Psychiatria 2017;14(2):75-77.

open access

Vol 14, No 2 (2017)
Prace poglądowe - nadesłane

Abstract

The aim of this review is to familiarize psychiatrists and other physicians with duloxetine, an antidepressant
with a dual mechanism of action combing inhibition of serotonin and norepinephrine transporters.

Abstract

The aim of this review is to familiarize psychiatrists and other physicians with duloxetine, an antidepressant
with a dual mechanism of action combing inhibition of serotonin and norepinephrine transporters.

Get Citation

Keywords

duloxetine, mode of action, depression, pain

About this article
Title

Pharmacological properties of serotonin and norepinephrine reuptake inhibitors — case of duloxetine

Journal

Psychiatria (Psychiatry)

Issue

Vol 14, No 2 (2017)

Article type

Review paper

Pages

75-77

Bibliographic record

Psychiatria 2017;14(2):75-77.

Keywords

duloxetine
mode of action
depression
pain

Authors

Przemysław Bieńkowski

References (17)
  1. Pehrson AL, Sanchez C. Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. CNS Spectr. 2014; 19(2): 121–133.
  2. Gosek P, Chojnacka M, Bieńkowski P, et al. [Effectiveness of ketamine in depressed patients resistant to ECT or rTMS therapy]. Psychiatr Pol. 2014; 48(1): 49–58.
  3. Warden D, Rush AJ, Trivedi MH, et al. The STAR*D Project results: a comprehensive review of findings. Curr Psychiatry Rep. 2007; 9(6): 449–459.
  4. Stahl SM. Depression and bipolar disorder. Stahl’s Essential Psychopharmacology. Cambridge University Press, Cambridge. ; 2008.
  5. Jarema M. Standardy leczenia farmakologicznego niektórych zaburzeń psychicznych. Via Medica, Gdańsk. ; 2015.
  6. Heitzman J, Vetulani J. Farmakoterapia depresji – współczesne podstawy teoretyczne i doświadczenia kliniczne. Termedia, Pozna. ; 2012.
  7. Frampton JE, Plosker GL. Duloxetine: a review of its use in the treatment of major depressive disorder. CNS Drugs. 2007; 21(7): 581–609.
  8. Schatzberg A, Nemeroff C. The American Psychiatric Publishing Textbook of Psychopharmacology. 2014.
  9. Chang T, Fava M. The future of psychopharmacology of depression. J Clin Psychiatry. 2010; 71(8): 971–975.
  10. Hamon M, Blier P. Monoamine neurocircuitry in depression and strategies for new treatments. Prog Neuropsychopharmacol Biol Psychiatry. 2013; 45: 54–63.
  11. Knadler MP, Lobo E, Chappell J, et al. Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2011; 50(5): 281–294.
  12. Białecka M, Sławek J. Interakcje leków w neurologii. Via Medica, Gdańsk. ; 2015.
  13. Kent JM. SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet. 2000; 355(9207): 911–918.
  14. Kiejna A. Oblicza depresji. Wybrane zagadnienia epidemiologiczne, kliniczne i społeczne. Medipress, Warszawa. ; 2008.
  15. Lunn MPT, Hughes RAC, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev. 2014(1): CD007115.
  16. D'Amato C, Morganti R, Greco C, et al. Diabetic peripheral neuropathic pain is a stronger predictor of depression than other diabetic complications and comorbidities. Diab Vasc Dis Res. 2016; 13(6): 418–428.
  17. Kennedy S, Gorwood P. Successful Management of Major Depressive Disorder. 2013.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest Via Medica sp. z o.o. sp. komandytowa, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl